MyoKardia
Develops novel, small molecule therapeutics that address key clinical needs of patients with genetic heart diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD20.2b (Public information from Oct 2020)
Share price
$224.91
San Francisco California (HQ)
Authorizing premium user...